Compare ASTC & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | GTBP |
|---|---|---|
| Founded | 1984 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 13.0M |
| IPO Year | 2020 | 2016 |
| Metric | ASTC | GTBP |
|---|---|---|
| Price | $6.19 | $7.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.7K | ★ 350.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | 3.75 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $0.22 |
| 52 Week High | $68.85 | $8.82 |
| Indicator | ASTC | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 70.84 |
| Support Level | $6.00 | $0.36 |
| Resistance Level | $6.48 | N/A |
| Average True Range (ATR) | 0.42 | 0.91 |
| MACD | -0.02 | 0.89 |
| Stochastic Oscillator | 4.38 | 66.49 |
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.